Follicular Lymphoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

FDA OKs Treatment for Advanced Follicular Lymphoma - Pharmacy Times



Curetoday.com
 
FDA OKs Treatment for Advanced Follicular Lymphoma 
Pharmacy Times
Officials with the FDA have approved obinutuzumab (Gazyva, Genentech) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma, according to the company's press release.
FDA Approves Gazyva for Advanced Follicular Lymphoma Curetoday.com
FDA Approves Genentech's Gazyva for Previously Untreated Advanced Follicular Lymphoma Business Wire (press release)
Gazyva OK'd for Previously Untreated Advanced Follicular Lymphoma Monthly Prescribing Reference
Journal of Clinical Pathways  -Healio  -Rare Disease Report 
all 8 news articles » 


Follicular Lymphoma Treatment Gazyva-Chemo Combo FDA ... - Lymphoma News Today



Follicular Lymphoma Treatment Gazyva-Chemo Combo FDA ... 
Lymphoma News Today
The FDA has approved Gazyva (obinutuzumab) in combination with chemotherapy as a first-line treatment for advanced follicular lymphoma.
FDA Approves Roche's Hemophilia A Biologic and Expands Indication for Leukemia Drug BioPharm International

all 2 news articles » 


FDA backs Roche's Gazyva in first-line follicular lymphoma - Reuters



FDA backs Roche's Gazyva in first-line follicular lymphoma 
Reuters
ZURICH, Nov 16 (Reuters) - The U.S. Food and Drug Administration on Thursday expanded approvals for Roche's Gazyva to include previously untreated follicular lymphoma, bolstering the Swiss drugmaker's efforts to strengthen its portfolio of blood cancer ...

 


Dr. Winter Discusses Copanlisib in Follicular Lymphoma - OncLive



Dr. Winter Discusses Copanlisib in Follicular Lymphoma 
OncLive
Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses copanlisib (Aliqopa) in follicular lymphoma. The intravenous pan-class I PI3K inhibitor copanlisib has shown predominant activity against the ...

 


Follicular Lymphoma: Audience Q&A - OncLive



OncLive
 
Follicular Lymphoma: Audience Q&A 
OncLive
Bruce Cheson, MD: In our last few minutes, we have some questions from the audience, some of which I think we got to. Such as, in which patients are we using obinutuzumab in place of rituximab? I think we got to that. The GADOLIN data I think would ...

and more » 


Gazyva Wins FDA OK for Untreated Advanced Follicular Lymphoma - Managed Care magazine



Pharmaceutical Processing
 
Gazyva Wins FDA OK for Untreated Advanced Follicular Lymphoma 
Managed Care magazine
Obinutuzumab (Gazyva, Genentech) has won FDA approval for the initial treatment of advanced follicular lymphoma after improving patients' survival in trials compared with rituximab-based regimens, the current standard of care. The FDA approved ...
US FDA Approves Roche's Gazyva for Untreated Follicular Lymphoma Fox Business
FDA OKs Gazyva for new lymphoma indication PharmaLive (press release)
FDA approves Gazyva for new indication The Pharma Letter

all 7 news articles » 


R-CVP Associated with 83% 8-Year OS for Advanced Symptomatic Follicular Lymphoma - OncLive



OncLive
 
R-CVP Associated with 83% 8-Year OS for Advanced Symptomatic Follicular Lymphoma 
OncLive
According to phase III results from the FOLL05 trial, the combination of rituximab (Rituxan) plus cyclophosphamide, vincristine, and prednisone (R-CVP) produced survival results comparable with standard-of-care regimens in patients with advanced ...

 


R-CHOP, R-CVP Confer Favorable Outcomes in Follicular Lymphoma - Cancer Therapy Advisor



Cancer Therapy Advisor
 
R-CHOP, R-CVP Confer Favorable Outcomes in Follicular Lymphoma 
Cancer Therapy Advisor
The open-label, multicenter, phase 3 FOLL05 trial included untreated patients with grade 1, 2, or 3a and Ann Arbor stage II to IV disease. This analysis included 504 evaluable patients. A long-term post-hoc analysis of the FOLL05 trial (ClinicalTrials ...

 


Study Links Early Progression to Poorer Survival Outcomes in Follicular Lymphoma Patients - Lymphoma News Today



Lymphoma News Today
 
Study Links Early Progression to Poorer Survival Outcomes in Follicular Lymphoma Patients 
Lymphoma News Today
New data from the GALLIUM Phase 3 trial (NCT01332968) shows that follicular lymphoma patients who progress within two years of immunochemotherapy have a 26-fold increased risk of death, compared to those without progression during that time.

 


Coexistence of diffuse large B-cell lymphoma, follicular lymphoma does not worsen prognosis - Healio



Coexistence of diffuse large B-cell lymphoma, follicular lymphoma does not worsen prognosis 
Healio
Patients with diffuse large B-cell lymphoma and follicular lymphoma at diagnosis did not have worse prognoses than patients with de novo DLBCL, according to study results. DLBCL is often identified at diagnosis of follicular lymphoma. The observation ...